The highly vascularised nature of breast cancer makes it a strong candidate for anti-angiogenic therapy ([@bib5]). Bevacizumab, a humanised anti-VEGF monoclonal antibody, is known to play a pivotal role in inhibiting angiogenesis and to improve perfusion in a variety of cancers ([@bib8]). A pivotal randomised phase III trial of metastatic breast cancer (MBC; ECOG2100) revealed that bevacizumab in combination with paclitaxel increased progression-free survival (PFS) but did not prolong overall survival (OS) compared with paclitaxel alone ([@bib11]). Thus, the addition of bevacizumab to chemotherapy failed to have the drastic impact on survival that was anticipated. Eribulin mesylate (eribulin) was recently approved as a first-in-class halichondrin B-based microtubule dynamics inhibitor for MBC patients and has very unique features according to results from a pooled analysis of phase III clinical trials (EMBRACE and Study301; [@bib19]). In contrast to bevacizumab, eribulin monotherapy was observed to prolong OS in MBC patients who had previously received anthracycline- or taxane-based chemotherapy over that of conventional chemotherapy. However, the PFS did not differ from that of controls in either arm of the study. Recent research has revealed that eribulin has a distinct biological profile with respect to its mechanism of anti-angiogenesis action ([@bib3]). Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to study a rat xenograph model of human breast cancer cells, Funahashi *et al* reported that tumour perfusion measured by average volume transfer constant value (K^trans^) increased in the tumour core within day 6 of eribulin infusion ([@bib6]). In contrast, the results of DCE-MRI studies of bevacizumab were highly ambiguous ([@bib9]; [@bib22]). A DCE-MRI study of bevacizumab in 70 patients with locally advanced breast cancer reported a strong decrease in multiple parameters, including tumour perfusion, concluding that bevacizumab administration was not associated with a histological response in the setting of neoadjuvant chemotherapy ([@bib4]). Hence, we hypothesise that the effects of eribulin on tumour vascularity may have a favourable impact on therapeutic outcomes and patient survival. We have recently established the use of near-infrared diffuse optical spectroscopic imaging (DOSI; TRS20; Hamamatsu Photonics K.K., Japan), a non-invasive functional imaging technique without ionising radiation exposure that quantifies *in vivo* tissue concentrations of oxyhaemoglobin (O~2~Hb), deoxyhaemoglobin (HHb), and oxygen saturation (SO~2~) in the breast ([@bib21]). Many investigators report that monitoring of tumour concentrations of O~2~Hb and HHb offers a novel opportunity for studying drug mechanisms in breast cancer and haemodynamic responses ([@bib18]; [@bib1]; [@bib14]). The microvascular concentration of O~2~Hb is dominant to arterial blood inflow, whereas accumulation of HHb inside a tumour occurs in response to impaired venous outflow that results in tissue hypoxia ([Figure 1A](#fig1){ref-type="fig"}). Oxygen saturation is considered a good indicator of tumour tissue oxygenation compared with that of surrounding normal breast.

We proposed that monitoring of these haemodynamic biomarkers could be used to improve our understanding of the biology of vascular remodelling and oxygenation response to these drugs. In this study, patients with advanced breast cancer were assigned to receive either eribulin monotherapy or single-agent bevacizumab followed by paclitaxel. Tumour concentrations of O~2~Hb, HHb, and SO~2~ at baseline and day 7 after the first drug infusion were measured. In addition, a pair of blood samples was collected during the observation window, and the changes in these plasma biomarkers were compared.

Methods:
========

Treatment and study design
--------------------------

Patients with histologically confirmed locally advanced stage III/IV breast cancer were enrolled in this study from June 2013 to July 2015. Locally advanced breast cancer was defined as a tumour \>5 cm in size or a tumour with fixation to the chest wall or skin. In this study, 15 patients were assigned to study A, receiving eribulin monotherapy (1.4 mg m^−2^, i.v.) weekly, with rest every third week. Fifteen patients were assigned to study B, receiving a single dose of bevacizumab (10 mg kg^−1^, i.v.) as an induction therapy (day 1) followed by weekly paclitaxel (80 mg m^−2^, i.v.) beginning on day 7. Combination therapy was continued in 14-day cycles, with paclitaxel administered on days 1, 8, and 15, and bevacizumab on day 1. Breast tissues were optically analysed using DOSI before and day 7 after the induction of eribulin monotherapy or single-agent bevacizumab (and before combination chemotherapy), and a pair of blood samples was collected at that time ([Figure 1B](#fig1){ref-type="fig"}). Tumour responses were examined with serial scans (baseline and after 2--4 courses of treatment) of DCE-MRI and 2-deoxy-2-^18^F-fluoro-[D]{.smallcaps}-glucose (FDG) positron emission tomography (PET) scans during treatment in routine practice. This study was approved by the SMUIMC Institutional Review Board (12--084, 13--132, 14--055) and informed consent was obtained from all individual participants included in the study. The study is registered on UMIN Clinical trial registration (000015837 and 000015839).

Functional optical imaging and haemodynamic biomarkers
------------------------------------------------------

We developed a TRS breast imaging system that uses time-correlated single-photon counting for measuring temporal response profiles of tissue against optical pulse inputs and enables quantitative analysis of light absorption and scattering in tissues according to the photon diffusion theory. Details of the TRS breast imaging system have been previously published ([@bib21]; [@bib12]). This approach was used to quantify absolute concentrations of O~2~Hb and HHb in tissues. The per cent SO~2~ was calculated as \[O~2~Hb\]/total \[Hb\] (O~2~Hb+HHb) × 100. We used an ultrasound-assisted optical probe to detect the largest tumour lesions and made a 10-mm square grid map in which the breast tumour was centred. The grid map of a tumour-bearing breast comprised 7 × 7 points with a 10-mm intervals between each point in the *x*--*y* dimension. Custom imaging software (DataBreastViewer, version 109; SincereTechnology Corp., Kanagawa, Japan) was used to perform 2D image processing and analysis. Representative optical images are shown in [Figure 1C](#fig1){ref-type="fig"}. Following ultrasound examination, the lesion region of interest (ROI), a circular area with a 2-cm radius, was traced manually over the area of high tHb concentration on the US map of the tumour. The size and position of ROI were fixed for data analysis of both baseline and 7 days after treatment visits. The mean concentrations of O~2~Hb and HHb and mean per cent SO~2~ were calculated. We monitored changes in the mean levels of these haemodynamic biomarkers during an observational window.

Circulating biomarkers
----------------------

Peripheral blood samples were obtained from patients who agreed to participate in the blood biomarker study. Plasma samples were separated by centrifugation and then aliquoted and stored at--80 °C until ELISA of free (non-bevacizumab bound) VEGF, bFGF, FLT-3L, EGF, G-CSF, TNFα, IL1b, IL4, IL6, IL8, IL10, and IL12p40 with a CLIA-certified multiplex protein array from Luminex Multiplex Assays Human Cytokine Magnetic 30-Plex and TGF-*β*1 using ELISA kits from R&D Systems. All samples were assayed in duplicate.

Statistical analysis
--------------------

We considered that at least 10 patients in each study group were required to compare variables between the two groups; 15 patients were registered to each group, making it a total of 30 patients during the 2-year pilot study period. Changes in biomarkers are reported as ratios and were assessed using the one-sample, two-sided, exact Wilcoxon test. Samples for which biomarker measurements were missing were excluded from the analysis. *P*\<0.05 was considered statistically significant. The data were analysed using Medcalc (Mariakerke, Belgium).

Results:
========

Haemodynamic response after treatment
-------------------------------------

Data from 14 patients who received eribulin and 15 patients who received bevacizumab were evaluable in the optical study. Patient characteristics and details of treatment are shown in [Table 1](#tbl1){ref-type="table"}. Optical imaging demonstrated that the average tumour HbO~2~ and HHb concentrations before treatment initiation were significantly higher than those of the contralateral normal breast tissue, as shown in [Figure 1D](#fig1){ref-type="fig"} (*P*\<0.0001 each). During eribulin treatment, tumour SO~2~ levels collectively increased on day 7 after the start of treatment (*P*=0.04), accompanied by a significant decrease in the tumour concentration of HHb (*P*=0.01) ([Figure 2A](#fig2){ref-type="fig"}). In the majority of patients receiving single-agent bevacizumab, the tumour concentration of O~2~Hb decreased (*P*=0.0003), but mean levels of tumour SO~2~ did not change at day 7 compared with baseline ([Figure 2B](#fig2){ref-type="fig"}) (*P*=0.2). The per cent decrease in O~2~Hb concentration and per cent SO~2~ in bevacizumab-treated patients were both significantly greater than those of eribulin-treated patients (both *P*=0.002) ([Figure 3A](#fig3){ref-type="fig"}). Representative cases are shown in [Figure 4](#fig4){ref-type="fig"}.

Changes in circulating biomarkers after treatment
-------------------------------------------------

Blood samples from 9 patients treated with eribulin and 10 patients treated with bevacizumab were analysed for circulating biomarkers and compared ([Figure 3B](#fig3){ref-type="fig"}). Significant decreases in plasma concentrations of VEGF and bFGF compared with baseline were observed in patients who received either eribulin or bevacizumab, with no difference between treatments. A significant decrease in plasma TGF-*β*1 concentration was seen only in patients treated with eribulin, and this decrease was significantly greater than that observed in patients treated with bevacizumab alone (*P*=0.002).

Therapeutic response to chemotherapy
------------------------------------

Tumour response measured using MRI and FDG-PET/CT was evaluated after 2--4 courses of chemotherapy ([Figure 3C](#fig3){ref-type="fig"}). Tumour size reduction and change in FDG-standardised uptake value (SUV)~max~ did not differ between eribulin-treated and bevacizumab-treated tumours (*P*=0.7 and 0.2, respectively).

Discussion:
===========

We hypothesised that optical imaging with DOSI could be used to monitor vascular remodelling and reoxygenation in response to agents, such as eribulin and bevacizumab, by measuring haemodynamic parameters in breast tumours. In this study, we observed that bevacizumab significantly decreased tumour O~2~Hb concentrations after the start of infusion. Because arterial vessels are rich in O~2~Hb, such a decrease may indicate vessel pruning and extensive inhibition of neo-angiogenesis by neutralization of circulating VEGF. In the course of vascular remodelling, endothelial cells (ECs) are induced from bone marrow and are properly reconstructed into the microvasculature and reoxygenation could consequently occur ([@bib7]). In fact, individuals showed a variety of tumour changes in SO~2~ after the start of bevacizumab. Although the overall tumour SO~2~ change did not differ significantly during the observation window, we previously reported that responding patients who had remarkable tumour shrinkage also had higher SO~2~ after treatment, whereas non-responding patients had lower SO~2~ after treatment ([@bib20]). These results suggest that when vascular remodelling works properly, bevacizumab should induce oxygenation. However, if the existing vasculature is destroyed without subsequent reorganisation, bevacizumab could lead to further hypoxia, contraindicating continuation of treatment.

In contrast to bevacizumab, eribulin treatment significantly decreased the tumour HHb concentration and consequently improved the tumour SO~2~. The haemodynamic response occurred irrespective of clinical response. A decrease in tumour HHb concentration may reflect processes counteracting elevated interstitial fluid pressure caused by high vessel permeability, low lymphatic drainage, and poor perfusion. Increased tumour SO~2~ could indicate increased perfusion and reoxygenation. The tumour O~2~Hb concentration did not decrease after the start of eribulin administration. How could eribulin induce tumour reoxygenation without neutralising circulating VEGF as seen with bevacizumab? One possible answer may lie in the results of biomarker studies of circulating cytokines, which revealed that treatment with either eribulin or bevacizumab significantly decreased plasma concentrations of VEGF and bFGF immediately after the start of drug infusion. Because VEGF and bFGF are both potent angiogenic cytokines, the inhibition of these two major factors indicates that eribulin and bevacizumab have anti-angiogenic properties ([@bib16]; [@bib10]). However, a decrease in plasma TGF-*β*1 concentrations was observed in patients treated with eribulin but not bevacizumab. These findings clearly indicate that the mechanism of action of these two agents differs ([Figure 5](#fig5){ref-type="fig"}).

TGF-*β*1 plays multiple roles in activating stromal cells in the tumour microenvironment, including ECs, fibroblasts, and immune cells necessary for cancer progression and metastasis ([@bib23]; [@bib13]). Multiple gene expression analyses have identified gene signatures associated with TGF-*β*1 signalling that are linked to the acquisition of epithelial--mesenchymal transition (EMT) and stem-cell-like phenotypes exhibited by breast cancer cells ([@bib17]). Yoshida *et al* reported that treatment of triple-negative breast cancer cells with eribulin monotherapy significantly upregulated mRNA expression levels of epithelial markers and simultaneously decreased the levels of several mesenchymal markers, leading to inhibition of neo-angiogenesis and the reversal of EMT in a TGF-*β*1-induced EMT model ([@bib24]). Because eribulin stabilises the microvasculature by binding to high-affinity sites on EC microtubules, use of this drug to treat tumours may provide further benefits by affecting stromal cells in the tumour microenvironment ([@bib15]; [@bib2]).

Conclusion:
===========

Optical imaging technology revealed that eribulin induced tumour reoxygenation after the start of infusion, but bevacizumab showed otherwise. The mechanism of haemodynamic action differs between these two agents. Treatment with eribulin but not bevacizumab leads to remodelling of the microvasculature through suppression of activated stromal cells.
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![(**A**) Monitoring tumour O~2~Hb and HHb illustrates arterial influx and venous efflux, respectively, inside the tumour. Tumour SO~2~ indicates the status of tissue oxygenation. (**B**) Breast tissues were analysed using optical imaging, and a pair of blood samples was collected before treatment and day 7 after the start of infusion. (**C**) Breast tumours were measured using an ultrasonography-assisted optical imaging system (TRS20, Hamamatsu Photonics K.K., Hamamatsu, Japan), and the contralateral normal breast was analysed as control. (**D**) Baseline concentrations of tumour O~2~Hb and HHb were significantly higher than those of the normal breast tissue.](bjc2016122f1){#fig1}

![Comparison of optical measurements of tumour O~2~Hb and HHb concentrations, and SO~2~ between baseline and day 7 after the start of eribulin (**A**) and bevacizumab (**B**).](bjc2016122f2){#fig2}

![Comparison of per cent change in tumour concentrations of O~2~Hb and HHb, and differences in tumour SO~2~ between eribulin and bevacizumab (**A**). Comparison of per cent change in plasma concentrations of VEGF, bFGF, and TGF-*β*1 between eribulin and bevacizumab (**B**). Tumour size reduction and changes in glucose metabolism after 2--4 courses of chemotherapy were compared between eribulin and bevacizumab (**C**).](bjc2016122f3){#fig3}

![**Case presentation of serial images using DCE-MRI, FDG-PET/CT, and DOSI in a responding tumour treated with eribulin (A) and bevacizumab (B) before and after the second cycle of treatment.**(**A**) A 40-year-old woman had parasternal lymph node metastasis detected 23 months after definitive surgery. (**B**) A 51-year-old woman had locally advanced breast cancer at diagnosis (T3N1M0). After the start of chemotherapy, both tumours showed significant shrinkage in size and decreased FDG uptake as measured by DCE-MRI and FDG-PET/CT scans 2--4 courses after the start of chemotherapy, respectively. The eribulin-treated tumour showed a decrease in HHb concentration and an increase in SO~2~. The bevacizumab-treated tumour showed decreased O~2~Hb and HHb concentrations coincident with an increase in SO~2~. The downward open arrow indicates the lesion location. The white arrow indicates enhancement of tumour blood vessels. CT=computed tomography; DCE-MRI=dynamic contrast-enhanced magnetic resonance imaging; DOSI=diffuse optical spectroscopic imaging; FDG=2-deoxy-2-^18^F-fluoro-D-glucose; HHb=deoxyhaemoglobin; O~2~Hb=oxyhaemoglobin; PET=positron emission tomography; SO~2~=oxygen saturation.](bjc2016122f4){#fig4}

![**Potential mechanisms of action of eribulin and bevacizumab on vasculature.**EMT=epithelial--mesenchymal transition; HHb=deoxyhaemoglobin; MET=mesenchymal-epithelial transition; O~2~Hb=oxyhaemoglobin; SO~2~=oxygen saturation.](bjc2016122f5){#fig5}

###### Patient characteristics

  **Characteristic**        **Eribulin (*****n*****=14)**   **Bevacizumab (*****n*****=15)**
  ------------------------ ------------------------------- ----------------------------------
  **Mean age**                                             
  y/o (s.d.)                         50.1 (9.4)                       52.4 (10.4)
  **Menstrual status**                                     
  Pre                                     6                                7
  Post                                    8                                8
  **Mean size**                                            
  mm (s.d.)                          48.4 (14.5)                      48.3 (24.7)
  **Histology**                                            
  IDC                                    14                                14
  ILC                                     0                                1
  **ER**                                                   
  Positive                               10                                11
  Negative                                4                                4
  **PgR**                                                  
  Positive                                5                                9
  Negative                                9                                6
  **HER2**                                                 
  Positive                                1                                0
  Negative                               13                                15
  **Distant metastasis**                                   
  Positive                                9                                6
  Negative                                5                                9
  **Prior therapy**                                        
  Anthracycline                          13                                6
  Taxane                                 13                                8
  Trastuzumab                             1                                0
  Endocrine therapy                       2                                3

Abbreviations: ER=oestrogen receptor; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; PgR=progesterone receptor.
